Skip to main content
. 2023 Oct 11;29(24):5079–5086. doi: 10.1158/1078-0432.CCR-23-1807

Table 2.

Treatment-related and immune-related adverse events.

Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%) Any grade, n (%)
Diarrhea 3 (27.3) 0 0 0 3 (27.3)
Rash 2 (18.2) 0 0 0 2 (18.2)
AST increased 2 (18.2) 0 0 0 2 (18.2)
Musculoskeletal stiffness 2 (18.2) 0 0 0 2 (18.2)
Nausea 1 (9.1) 0 0 0 1 (9.1)
Vomiting 1 (9.1) 0 0 0 1 (9.1)
Stomatitis 0 1 (9.1) 0 0 1 (9.1)
Pruritus 1 (9.1) 0 0 0 1 (9.1)
Malaise 1 (9.1) 0 0 0 1 (9.1)
Pyrexia 1 (9.1) 0 0 0 1 (9.1)
Decreased appetite 1 (9.1) 0 0 0 1 (9.1)
ALT increased 1 (9.1) 0 0 0 1 (9.1)
White blood cell count decreased 0 1 (9.1) 0 0 1 (9.1)
Neutrophil count decreased 0 1 (9.1) 0 0 1 (9.1)
Lymphocyte count decreased 0 1 (9.1) 0 0 1 (9.1)
Anemia 0 1 (9.1) 0 0 1 (9.1)
Pneumonitis 0 1 (9.1) 0 0 1 (9.1)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.